Bupropion in the Treatment of Pathological Gambling
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Bupropion Versus Placebo in the Treatment of Pathological Gambling|
|Study Start Date:||July 2002|
|Study Completion Date:||April 2006|
|Primary Completion Date:||May 2005 (Final data collection date for primary outcome measure)|
Active Comparator: Subjects receivng Bupropion
The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
18 subjects in this randomly controlled double blind study received bupropion.
Placebo Comparator: Subjects receiving Placebo
The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
21 subjects received Placebo.
As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.
Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00055393
|United States, Iowa|
|Roy J. and Lucille A. Carver College of Medicine, University of Iowa|
|Iowa City, Iowa, United States, 52242|
|Principal Investigator:||Donald W Black, MD||University of Iowa|